Status:
COMPLETED
Efficacy of Perineural Injection With Dextrose Versus Therapy Conventional Physics in Patients With Bell's Palsy
Lead Sponsor:
Celia Itxelt Infante Castro
Collaborating Sponsors:
ARIANA GUADALUPE MARTINEZ SILVA
MARIA DE LOS ANGELES HERNANDEZ SANCHEZ
Conditions:
Bell´s Palsy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Bell´s Palsy, a lower motor neuron injury that causes facial asymmetry due to facial weakness ranging from mild to total paralysis. Most of cases without determining a definitive established cause. Th...
Detailed Description
This study aims to evaluate the efficacy of dextrose perineural injection therapy while motivating and serving as a foundation for future studies to compare or create alternatives and therapeutic meth...
Eligibility Criteria
Inclusion
- Patients with Bell\'s Palsy who:
- Age 18 years and older.
- Both male and female.
- Duration of symptoms longer than 6 days.
- Apparently healthy, without any associated comorbidities such as diabetes mellitus, obesity, hypothyroidism, hyperthyroidism, metabolic syndrome, or any neurological disorder.
- Grade III (moderate dysfunction), IV (moderate to severe dysfunction), V (severe dysfunction), or VI (total paralysis) according to the House-Brackmann Classification.
- Exclusive attention from UMF 2, 3, 4, 6, 11, 16, 29, 34, 35, 42, 94, 120 and the Physical Medicine and Rehabilitation Unit in the central region (employers and beneficiaries).
- Exclusive attention from the UMF belonging to Mexico City (beneficiaries only).
- Patients willing to participate in the study confirmed with signed informed consent.
Exclusion
- Active smokers.
- Patients with central facial paralysis.
- Patients with peripheral facial paralysis secondary to tumors or surgical treatment.
- Patients experiencing more than second episode of Peripheral Facial Paralysis.
- Patients with cognitive and/or mental impairments.
- Patients undergoing additional private therapy.
- Patients with bilateral facial paralysis.
- Pregnant patients.
- Patients unwilling to participate in the study.
- Patients who have received prior rehabilitation, laser, electrotherapy, or acupuncture.
- Elimination Criteria:
- Patients who do not attend rehabilitation sessions.
- Patients diagnosed with Sars-cov2 infection during the study.
- Patients who discontinue treatment.
- Patients developing other pathologies requiring special treatment.
- Patients wishing to withdraw from the study.
Key Trial Info
Start Date :
February 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06551779
Start Date
February 9 2024
End Date
May 31 2024
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unidad de Medicina Física Y Rehabilitacion Region Centro Imss
Mexico City, Cuauhtemoc, Mexico, 06500